Summit Creek Advisors LLC Buys 15,690 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Summit Creek Advisors LLC raised its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 4.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 363,898 shares of the medical research company’s stock after purchasing an additional 15,690 shares during the quarter. Summit Creek Advisors LLC’s holdings in NeoGenomics were worth $6,958,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of NEO. Commonwealth Equity Services LLC boosted its position in shares of NeoGenomics by 3.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 25,647 shares of the medical research company’s stock valued at $562,000 after acquiring an additional 945 shares in the last quarter. BlackRock Inc. boosted its position in NeoGenomics by 8.0% in the second quarter. BlackRock Inc. now owns 14,925,327 shares of the medical research company’s stock valued at $327,462,000 after buying an additional 1,100,263 shares in the last quarter. Prudential Financial Inc. boosted its position in NeoGenomics by 8.1% in the second quarter. Prudential Financial Inc. now owns 163,570 shares of the medical research company’s stock valued at $3,589,000 after buying an additional 12,250 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in NeoGenomics by 33.7% in the second quarter. Envestnet Asset Management Inc. now owns 36,908 shares of the medical research company’s stock valued at $810,000 after buying an additional 9,309 shares in the last quarter. Finally, King Luther Capital Management Corp boosted its position in NeoGenomics by 11.2% in the second quarter. King Luther Capital Management Corp now owns 159,567 shares of the medical research company’s stock valued at $3,501,000 after buying an additional 16,117 shares in the last quarter. Institutional investors own 84.92% of the company’s stock.

Shares of NASDAQ NEO traded up $0.20 during trading on Thursday, reaching $20.41. The company had a trading volume of 3,363 shares, compared to its average volume of 958,798. NeoGenomics, Inc. has a 52 week low of $11.05 and a 52 week high of $26.89. The stock has a market cap of $2.12 billion, a PE ratio of 157.65 and a beta of 0.92. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.52 and a current ratio of 4.67. The business’s 50 day moving average price is $21.59 and its 200-day moving average price is $22.45.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, July 30th. The medical research company reported $0.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.02. NeoGenomics had a net margin of 0.57% and a return on equity of 4.97%. The company had revenue of $101.71 million during the quarter, compared to the consensus estimate of $97.32 million. During the same period in the previous year, the firm posted $0.05 earnings per share. The company’s revenue was up 50.1% on a year-over-year basis. Equities analysts anticipate that NeoGenomics, Inc. will post 0.19 earnings per share for the current year.

A number of research firms have commented on NEO. Leerink Swann set a $30.00 price target on shares of NeoGenomics and gave the company a “buy” rating in a research report on Wednesday, July 31st. Needham & Company LLC set a $27.00 price target on shares of NeoGenomics and gave the company a “buy” rating in a research report on Wednesday, July 31st. Benchmark set a $27.00 price target on shares of NeoGenomics and gave the company a “buy” rating in a research report on Wednesday, July 31st. BidaskClub upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research report on Saturday, October 5th. Finally, Raymond James boosted their price target on shares of NeoGenomics from $23.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $24.75.

In other NeoGenomics news, Director Steven C. Jones sold 181,339 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $24.92, for a total value of $4,518,967.88. Following the completion of the transaction, the director now directly owns 245,234 shares of the company’s stock, valued at $6,111,231.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider William Bonello sold 17,000 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $24.83, for a total transaction of $422,110.00. Following the completion of the transaction, the insider now directly owns 23,735 shares of the company’s stock, valued at $589,340.05. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 241,370 shares of company stock valued at $6,017,680. Insiders own 8.80% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Featured Story: Initial Public Offering (IPO)

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.